ReviewMycoses2026
Pulmonary Cryptococcosis in Apparently Immunocompetent Hosts: Host Susceptibility, Occult Immunodeficiency and Clinical Implications.
Review in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary cryptococcosis (PC) in apparently immunocompetent hosts-now the majority of non-HIV cases in Asia-cannot be explained by the traditional opportunistic infection paradigm. Three epidemiological observations point toward occult immune susceptibility: familial clustering documented in multiple case reports and small family studies despite shared environmental exposure, normal routine immunological screening, and species-specific infection patterns between Cryptococcus neoformans and Cryptococcus gattii. We propose a three-layer framework: upstream genetic variants in pattern recognition, Fcγ receptor, complement-lectin, and macrophage-regulatory loci (Layer 1) act in concert with intermediate immune phenotypes (Layer 2)-the genetically influenced IL-17/Th17 axis and IgG2 subclass deficiencies, and acquired anti-GM-CSF neutralising autoantibodies-that are proposed to converge on alveolar macrophage dysfunction and defective pulmonary fungal clearance (Layer 3). The three Layer 2 phenotypes differ substantially in evidence strength: anti-GM-CSF autoantibodies have reached clinical validation; IgG2 deficiency remains a mechanistic hypothesis; and IL-17/Th17 deficiency is supported by a single unreplicated study and should be treated as preliminary. This framework is hypothesis-generating, derived from candidate-gene studies, limited immunophenotyping data, and animal models; it has not been validated by genome-wide association studies or prospective functional research, and its clinical value requires confirmation by higher-quality evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.